Physician profile
Narinder Bajwa
NPI 1750332920
$1,920.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $64.26 · 2022: $49.55 · 2023: $144 · 2024: $25.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $718.60 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $228.05 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $191.64 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $174.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $141.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $133.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.07 | 2019-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $51.06 | 2019 | |
| Abbott Laboratories | $49.37 | 2019 | |
| Medtronic Vascular, INC. | $35.36 | 2019 | |
| Boston Scientific Corporation | $27.85 | 2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Lundbeck LLC | $19.82 | 2019 | |
| Allergan, INC. | $18.67 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $18.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Bajwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.